Consistent with abnormal TP53 contributing to PC progression, other large scale studies using combined immunohistochemistry and sequencing approaches have shown that TP53 mutations occur in approximately 5% of primary tumors and at much higher frequencies in lymph node metastases (16%) and castrate-resistant (26%) tumors [21], [22]. The gene discussed is TP53; the disease is pachyonychia congenita.